Month: September 2015

PRRT offers longer progression free survival

New results from the NETTER-1 study that compared Sandostatin LAR 60mg versus treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera have been made available. These findings, released at the 2015 European Cancer Congress, show that for patients living with…

Continue Reading PRRT offers longer progression free survival